Hims & Hers Stock Tumbles 15% as Novo Outpaces Rivals in Weight-Loss Drug War | MarketWire
Hims & Hers announced plans to halt development of a Wegovy alternative as Novo Nordisk dominates the weight-loss drug race. Here's what investors need to know.